Heiko Hermeking
Overview
Explore the profile of Heiko Hermeking including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
6700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pretzsch E, Peschel C, Rokavec M, Torlot L, Li P, Hermeking H, et al.
Lab Invest
. 2025 Feb;
105(5):104107.
PMID: 39954853
FOLFIRI, a combination of folinic acid, 5-fluorouracil, and irinotecan, is one of the recommended first-line chemotherapeutic treatments for metastatic colorectal cancer. Unfortunately, acquired FOLFIRI resistance represents a common obstacle in...
2.
Konig J, Rokavec M, Oner-Ziegler M, Fei Y, Hermeking H
Cell Death Differ
. 2024 Oct;
32(2):225-241.
PMID: 39425000
We have previously shown that general deletion of the gene encoding the p53-inducible Mir34a microRNA enhances the number and invasion of colitis-associated colorectal cancers (CACs) in mice. Since the p53-pathway...
3.
Kaller M, Forne I, Imhof A, Hermeking H
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730591
Background: Loss of the p53-inducible in p53-proficient CRC cell lines results in increased sensitivity to DNA-damaging chemotherapeutics. Here, we comprehensively analyze how affects the p53-induced transcriptional program. Methods: Using a...
4.
Chou J, Kaller M, Rokavec M, Liu F, Hermeking H
Cancer Commun (Lond)
. 2024 Jan;
44(3):433-437.
PMID: 38225895
No abstract available.
5.
Rokavec M, Jaeckel S, Hermeking H
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001576
We have previously shown that the extracellular matrix and basement membrane protein Nidogen1 (NID1) is secreted by more malignant, mesenchymal-like CRC cells and induces the epithelial-mesenchymal transition (EMT) and promotes...
6.
Liu C, Rokavec M, Huang Z, Hermeking H
Cell Death Dis
. 2023 Oct;
14(10):707.
PMID: 37898661
Aspirin and its active metabolite salicylate have emerged as promising agents for the chemoprevention of colorectal cancer (CRC). Moreover, aspirin suppresses the progression of established CRCs. However, the underlying molecular...
7.
Du Y, Rokavec M, Hermeking H
Int J Biol Sci
. 2023 Sep;
19(13):4103-4122.
PMID: 37705742
Elevated expression of c-MYC and inactivation of represent two of the most common alterations in colorectal cancer (CRC). However, c-MYC and defective p53 are difficult to target therapeutically. Therefore, effectors...
8.
Rokavec M, Ozcan E, Neumann J, Hermeking H
Cancer Res Commun
. 2023 Sep;
3(8):1689-1700.
PMID: 37654625
Significance: We identified and validated a 15-gene expression signature for robust prognostication and stratification of patients with stage II colorectal cancer, with superior performance when compared with currently used biomarkers....
9.
Chan T, Hermeking H, Lengauer C, Kinzler K, Vogelstein B
Nature
. 2023 Aug;
621(7977):E28-E29.
PMID: 37626188
No abstract available.
10.
Huang Z, Kaller M, Hermeking H
Cell Death Differ
. 2023 Jul;
30(8):2017-2034.
PMID: 37488217
The miR-34a and miR-34b/c encoding genes represent direct targets of the p53 transcription factor, and presumably mediate part of the tumor suppressive effects of p53. Here, we sought to determine...